Acetone-free nail polish remover pads: toxicity in a 9-month old Acetone-free nail polish removers are widely used and perceived as safe. However, an ingredient c-butyrolactone (GBL) is readily converted into c-hydroxybutyrate (GHB), which has well-known toxic effects. A previously well 9-month-old child was found sucking on two nail polish remover pads. The period the pads were in his mouth did not exceed 1 min. Within 15 min, he vomited and became drowsy; after 30 min he was in a coma with a Glasgow Coma Score (GCS) of 3. Oxygen was administered while he was transported to the emergency department by ambulance.
Acetone-free nail polish removers are widely used and perceived as safe. However, an ingredient c-butyrolactone (GBL) is readily converted into c-hydroxybutyrate (GHB), which has well-known toxic effects. A previously well 9-month-old child was found sucking on two nail polish remover pads. The period the pads were in his mouth did not exceed 1 min. Within 15 min, he vomited and became drowsy; after 30 min he was in a coma with a Glasgow Coma Score (GCS) of 3. Oxygen was administered while he was transported to the emergency department by ambulance.
On arrival at the emergency department, 60 min post ingestion, his GCS had improved to 6. He had hypotension, bradycardia and was in shock. Blood gases showed a mild respiratory acidosis. Biochemistry was normal. He responded well to fluid resuscitation. By 90 min, his GCS had recovered to 12. This progressed to hyperalertness and extreme giddiness that persisted for several hours. His pupils, which were initially constricted and poorly reactive, became more responsive. The child made a complete recovery within 8 h of ingestion.
This child developed coma and cardiorespiratory compromise after briefly sucking on two nail polish remover pads. We presume that this was due to rapid absorption of ingredients of this product through buccal, sublingual and oral routes. Conditioning nail polish remover pads contain the following as principal ingredients: GBL (84%), butoxyethanol (10%), diethylene glycol (2%), panthenol (1%) and propylene glycol (1%). GBL is rapidly metabolised to GHB, which causes a pattern of toxicity similar to that seen here.
Another case of poisoning and severe toxicity in a 15-month-old child who sucked on an identical product was reported. He became comatose with cardiorespiratory collapse requiring ventilation and intensive care, but made a complete recovery. 1 When contacted after the incident, the manufacturers responded: ''as a cautionary measure, action has been taken to reformulate the products to add a material called Bitrex that makes it more unpalatable and further reduces the risk of unintentional ingestion, a keep out of reach of children message is to be included on the packaging''.
Acetone-free nail polish removers are widely used and were perceived as safe. Our case highlights the dangers of GBL-containing products when ingested. TW2 and TW3 bone ages: time to change?
In 1983, the Tanner2Whitehouse 2nd edition (TW2) system of bone ageing was published and has remained the most widely used system in the UK. 1 Several studies have shown that children are maturing more rapidly and reaching a given skeletal maturity score (SMS) at an earlier chronological age. 2 In view of this finding, Tanner and colleagues published a revised 3rd edition for bone ageing in 2001 (TW3). 3 This updated the relationship of the SMS to bone age to deal with the secular trend that had occurred in skeletal maturation since the previous edition. However, this new version has received little publicity and does not seem to be widely used in the UK .
To explore the changes that have occurred between these two publications, we retrospectively compared TW2 RUS (radius, ulna and short bones) and TW3 RUS bone age assessments in 142 children in two diagnostic groups (idiopathic short stature or constitutional delay in growth and puberty and congenital adrenal hyperplasia) with a range of bone ages from delayed to advanced.
The descriptions and manual ratings remain the same for TW2 and TW3, and the calculation of the SMS is the same. However, the centile charts for RUS SMS against age have changed between versions 2 and 3.
TW3 estimates of bone age were younger than TW2, and both were delayed compared with the chronological age in children with idiopathic short stature and constitutional delay in growth and puberty (table 1) . For children with congenital adrenal hyperplasia, TW3 estimates of bone age were younger than TW2, and both were advanced compared with chronological age. TW2 and TW3 estimates of bone age are not interchangeable. Figure 1 shows how the differences between the two versions change with increasing maturity score for boys and girls.
The SMS on which the bone age is based is the fundamental unit of measurement for bone maturity assessment, and should be considered alike any other anthropometric measure, such as height or weight. As such, the SMS centile charts require periodic updating if they are to be used to assess development. 4 5 Our results show that TW3 bone age differed from TW2 bone age in the two diagnostic groups studied, with the differences becoming more marked with increasing maturity. This suggests that the currently widely used TW2 bone age may not reflect an accurate skeletal maturity PostScript............................................................................................... ...
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Competing interests: None. Figure 1 Difference between Tanner-Whitehouse 2nd edition (TW2) and TW3 against maturity score for girls and boys. Points represent individual patients. 
Compliance with inhaled corticosteroids is important when considering adrenal suppression
We read with interest the article by Paton et al We recently published the results of standard-dose Synacthen tests in children recommended >1000 mg of fluticasone proprionate per day. Of the 29 children tested, 3 were found to have complete adrenal suppression. 2 In his editorial, Russell 3 highlights compliance with the treatment as likely to be important, given the fact that not all patients taking high-dose fluticasone proprionate have adrenal failure. In our study, the first of its kind to our knowledge in this context, we examined compliance in terms of the actual amount of fluticasone proprionate prescribed over the past year in primary care relative to that recommended by the hospital specialist. The three children with adrenal suppression had actually been prescribed only a median of 493 mg fluticasone proprionate per day over the past year, compared with a median of 433 mg in the normal group. Overall, there was an inverse correlation between the actual prescribed daily dose of fluticasone proprionate and the peak cortisol response to Synacthen (r = 20.44, p = 0.03). 2 Our study was relatively small in size and used a pragmatic measure of compliance; however, the results suggest that compliance with treatment should be considered and that in reality children with adrenal suppression may be receiving smaller doses of fluticasone proprionate than we think.
A view from the other side of the table
The transition from specialist trainee to consultant is an important one. Many newly appointed consultants feel inadequately prepared to deal with new management roles such as sitting on an interview panel. 1 2 Conducting an interview can be as challenging as attending one. One has to exercise keen judgement to separate the cream out of the multitude of applicants. Courses to hone individuals' techniques for conducting interviews are run by most trusts. However, experience from courses is nowhere as close to the real-life experience of conducting interviews. I recently had the opportunity of being part of an esteemed panel of interviewers. The post in question was that of specialist registrar in paediatrics in the northern deanery.
Seven members were present on the panel, of whom I was the only registrar, but my role was as important as that of anyone else. My first task was to produce a short list of applicants. After getting a grasp of the person specification, which helps to identify the essential and desirable criteria of each candidate, I went through each application carefully. In effect, candidates were not shortlisted if they did not meet all essential criteria. Desirable criteria included experience of research, publications, certificate in medical education, prizes and other achievements, or specialist clinical experience-for instance, echocardiography. The more of these a candidate possessed, the better their chances of making it to the short list. I scored each application independently and so did all the other panel members. The scores were then totalled and a merit list created. We aimed at producing a candidate short list, the number of candidates included on it being double the number of posts being contested. If a wide variation in scores between panelists was noticed for any individual candidate, the applicants' credentials were re-evaluated and discussed, and decision made by consensus.
I prepared for the interview, to ask questions, rather than answer them. Scoring was carried out based on structured guidelines. This, for me, was an excellent learning experience. I had the opportunity to learn different methods of questioning and to gain insight into how responses are assessed. I am now wiser about what impresses panellists and what does not. This will no doubt enrich my own interviewing skills and prove invaluable when I compete for posts in the future. After the last candidate was interviewed, scores from the panellists were compared. I was pleased (and relieved) to discover that my scoring of candidates was in agreement with that of most other panel members.
I strongly feel that deaneries and trusts should try this system more often to provide their future consultants with a taste of the process of candidate selection. The success of this exercise, if indeed adopted, will depend on whether or not the trainees participate alongside other panel members in the entire process of job selection, right from short listing to ultimately deciding on the successful candidates.
